HOPE Therapeutics Begins Patient Treatments with Zeta Surgical’s AI-Powered TMS System — NRx Pharmaceuticals, Inc.

Event summary

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, has begun treating patients using Zeta Surgical’s FDA-cleared Zeta TMS Navigation System at its clinics in West Palm Beach and Sarasota, Florida.
The system provides AI-powered, sub-millimetric image guidance for TMS procedures, enhancing precision in treating Major Depressive Disorder and other CNS conditions.
This milestone marks the transition from research deployment to active patient care, aligning with NRx’s planned SPARC-TMS trial combining NRX-101 with robotic-enabled TMS.

The big picture

This development underscores the growing trend of AI-driven precision in mental health treatments, positioning NRx Pharmaceuticals as a key player in interventional psychiatry. The strategic alignment with Zeta Surgical’s technology enhances HOPE Therapeutics’ capability to deliver targeted therapies, potentially differentiating it in a competitive landscape.

What we're watching

Clinical Integration: How the integration of Zeta’s TMS Navigation System into HOPE’s outpatient workflows will impact treatment outcomes for patients with Major Depressive Disorder.
Regulatory Alignment: Whether the FDA-cleared system will accelerate NRx’s planned SPARC-TMS trial and its approval process for NRX-101.
Market Expansion: The pace at which HOPE Therapeutics can scale this technology across additional clinics and treatment facilities.